Friday, 5 June 2015

Global Intravenous (I.V.) Iron Drugs Market Report: 2015 Edition

Iron deficiency anemia is the most common form of anemia throughout the world. It is estimated that two billion people suffer from iron deficiency anemia worldwide. To address iron deficiency, iron therapy is important being the critical factor in the production of red blood cells. Around 4.5 million Americans are diagnosed and suffering from iron deficiency anemia (IDA).
Generally, daily oral iron is the first line therapy for most IDA patient but for many patients oral iron therapy fails as a consequence of compliance, efficacy and side effects like constipation and gastro intestinal disorders. When oral supplements fail to meet the requirement, intravenous (I.V.) iron therapy is used, in which iron is directly injected with a needle into a vein. Iron given intravenously allows larger amounts of iron to be provided to patients while avoiding many of the side effects and treatment compliance issues associated with oral iron, and can result in faster rises in hemoglobin levels. In the US, a small fraction of non-dialysis CKD patients who are diagnosed with IDA are currently being treated with I.V. iron, and thus a significant opportunity is there for the market.
The key factors driving growth of the global I.V. iron industry include iron deficiency in hemodialysis patient cases, growing number of ERSD patients, prevalence of iron deficiency in women, increasing global healthcare expenditure, increasing global ageing population and large potential in new therapeutic areas. Some of the noteworthy trends and developments of this industry are penetration of I.V. iron in obstetrics and gynecology area, new product development and increase in awareness of disease. However, the growth of this sector is hindered by potential risks of using I.V. iron, emerging anemia management therapies and strict regulatory structures.
The report provides a comprehensive study of iron product market and I.V. iron market globally. It also provides detailed information for key regional markets of I.V iron industry. The competition in the global I.V. iron market is stiff among large players like Galenica Group, AMAG Pharmaceuticals Inc. and Actavis Plc. All these companies have been profiled in the present report highlighting their key financials and business strategies for growth.
By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests. 

Table Of Content:
1. Overview
1.1 I.V. Iron Application Areas
1.1.1 I.V. Iron Application in Nephrology
1.2 Iron Deficiency - Anemia
1.2.2 Iron Deficiency Metrics
1.3 I.V. Iron Therapies for Anemia Treatment
2. Market Analysis
2.1 Global Iron Product Market
-Market Value
-Market Segments
2.2.1 Global I.V. Iron Drug Market
-Market Value
-Product Share
2.2 Regional Analysis
2.2.1 The US I.V. Iron Drug Market
-Market Value
-Product Share
-Non-Dialysis IV Iron Market
2.2.2 European I.V. Iron Drug Market
-Market Value
-Product Share
2.2.3 Australian I.V. iron Drug Market
-Market Value
-Product Share
For any enquires before buying, connect with us @ enquiry@orbisresearch.com

About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:
Hector Costello
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas - 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019
Follow us on Twitter: https://twitter.com/orbisresearch


No comments:

Post a Comment